HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Choosing Wisely endorsements give ASH opportunity to ‘make a difference’ beyond hematology
• Update on use of irreversible electroporation for locally advanced pancreatic cancer
• Imatinib in 2016: What will the era of generic targeted therapy for cancer look like? Michael J. Mauro, MD
• Melanoma/Skin Cancer Drugs in the Pipeline
• New data on late treatment effects should change physician–patient discussions John Sweetenham, MD, FRCP, FACP
• FDA approves EMEND to prevent nausea, vomiting after moderately emetogenic chemotherapy
• FDA approves Halaven for metastatic, unresectable liposarcoma
• FDA grants breakthrough therapy designation to Lynparza for certain types of prostate cancer
• FDA grants fast track designation to TPIV 200 for ovarian cancer
• FDA grants orphan drug designation to IMCgp100 for uveal melanoma
• FDA grants orphan drug designation to TRC105 for soft tissue sarcoma
• FDA grants third breakthrough therapy designation to venetoclax
• ADT may increase cardiac mortality among men with unfavorable-risk prostate cancer, comorbidities
• Chemoradiotherapy effective for elderly patients with limited-stage small cell lung cancer
• Common functional tests detect cognitive deficits in pediatric patients with brain tumors
• Early diagnosis, chemotherapy response influence renal survival in LCDD
• Family history, thrombophilia may predict VTE recurrence
• Fertility concerns may cause women to forgo, cease endocrine therapy
• Genomic variant predicts mortality, recurrence risks for clear cell renal cell carcinoma
• HLA biomarker may predict GVHD risk following HSCT
• NCI-designated cancer centers call for increase in HPV vaccination
• Nexavar/HAIC with cisplatin yields favorable results for HCC
• Nodal irradiation fails to improve OS following breast-conserving surgery
• PALB2, BARD1 mutations associated with ovarian cancer
• PCP intervention can improve smoking cessation following lung cancer screening
• Prognostic features predict durable response to dabrafenib, trametinib
• Recipients of solid-organ transplants more likely to die of cancer
• Residual platinum levels may produce late effects among survivors of testicular cancer
• Socioeconomic factors linked to surgery receipt, survival in early-stage pancreatic cancer
• Total laryngectomy may be underused in advanced larynx cancer
• Adjuvant denosumab may prolong DFS among postmenopausal women with breast cancer
• ASTRO appoints scientific affairs director
• Children’s Hospital Los Angeles names director of Center for Personalized Medicine
• Children’s Research Institute at Children’s Mercy appoints chief scientific officer
• Emory University, Winship Cancer Institute name department chairman
• Vanderbilt University Medical Center names chief of surgical oncology
• Adjuvant therapy performed at high-volume center improved OS in pancreatic cancer
• Advanced gastric cancer patients may have better overall survival with mFOLFOX7 followed by mFOLFIRI
• PD-1 blockade promising in MMR deficient GI cancers
• Ziv-aflibercept does not improve FOLFOX efficacy in gastric, GE junction cancer
• Meeting Update: Experts provide further insight on findings presented at Gastrointestinal Cancers Symposium